All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

eribulin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
antineoplastics; mitotic inhibitors, tubulin binders	4171	253128-41-5

Description:

Molecule

Description

Molfile Inchi Smiles Synonyms: eribulin mesylate eribulin halaven E7389 eribulin mesilate

Eribulin inhibits the growth phase of microtubules without affecting the shortening phase and sequesters tubulin into nonproductive aggregates. Eribulin exerts its effects via a tubulin-based antimitotic mechanism leading to G2/M cell-cycle block, disruption of mitotic spindles, and, ultimately, apoptotic cell death after prolonged mitotic blockage. In addition, eribulin treatment of human breast cancer cells caused changes in morphology and gene expression as well as decreased migration and invasiveness in vitro. In mouse xenograft models of human breast cancer, eribulin treatment was associated with increased vascular perfusion and permeability in the tumor cores, resulting in reduced tumor hypoxia, and changes in the expression of genes in tumor specimens associated with a change in phenotype. Molecular weight: 729.91 Formula: C40H59NO11 CLOGP: 0.14 LIPINSKI: 2 HAC: 12 HDO: 2 TPSA: 146.39 ALOGS: -3.96 ROTB: 4 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

None

ADMET properties:

Property	Value	Reference
Vd (Volume of distribution)	1.46 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	0.75 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.43 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	37.80 hours	Lombardo F, Berellini G, Obach RS
S (Water solubility)	10.40 mg/mL	Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
kinase-safety-class	ACVR2B,AXL,BRAF,CAMK2D,CDK5,EIF2AK3,GRK2,ITK,NTRK2,PDK1,PDK2,PDK4,PRKDC	13
pfas-class	PFAS structural alert (1 = True, 0 = False)	0

Approvals:

Date	Agency	Company	Orphan
March 17, 2011	EMA
Nov. 15, 2010	FDA	EISAI INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Myelosuppression	1796.02	32.93	550	12973	53041	90561883
Malignant neoplasm progression	1503.26	32.93	572	12951	106298	90508626
Neutropenia	1482.93	32.93	702	12821	224202	90390722
Febrile neutropenia	859.14	32.93	434	13089	157915	90457009
Neutrophil count decreased	674.55	32.93	288	13235	71244	90543680
Metastases to bone	442.90	32.93	160	13363	25345	90589579
White blood cell count decreased	439.24	32.93	286	13237	166823	90448101
Neuropathy peripheral	436.69	32.93	265	13258	136705	90478219
Metastases to liver	431.18	32.93	162	13361	28645	90586279
Interstitial lung disease	359.95	32.93	191	13332	76214	90538710
Leukopenia	333.99	32.93	200	13323	100510	90514414
Pseudocirrhosis	279.44	32.93	56	13467	888	90614036
Disease progression	273.55	32.93	209	13314	156406	90458518
Metastases to lung	214.21	32.93	83	13440	15908	90599016
Neoplasm progression	203.07	32.93	109	13414	44377	90570547
Breast cancer metastatic	200.77	32.93	78	13445	15054	90599870
Metastases to central nervous system	176.10	32.93	74	13449	17468	90597456
Palmar-plantar erythrodysaesthesia syndrome	157.55	32.93	79	13444	27944	90586980
Mucosal inflammation	156.73	32.93	101	13422	57524	90557400
Metastases to lymph nodes	126.38	32.93	52	13471	11637	90603287
Osteonecrosis of jaw	125.10	32.93	76	13447	39027	90575897
Thrombocytopenia	109.65	32.93	145	13378	208580	90406344
Pyrexia	96.71	32.93	265	13258	660220	89954704
Haematotoxicity	93.74	32.93	43	13480	12492	90602432
Anaemia	92.08	32.93	178	13345	352624	90262300
Hepatic function abnormal	85.52	32.93	64	13459	46224	90568700
Metastases to skin	80.01	32.93	24	13499	2116	90612808
Hormone receptor positive breast cancer	77.92	32.93	19	13504	762	90614162
Pleural effusion	73.43	32.93	87	13436	111904	90503020
Breast cancer	68.85	32.93	60	13463	53701	90561223
Stomatitis	63.67	32.93	132	13391	274566	90340358
Hyperchlorhydria	60.79	32.93	19	13504	1922	90613002
PIK3CA-activated mutation	56.02	32.93	16	13507	1188	90613736
Pneumonitis	55.96	32.93	49	13474	44121	90570803
Abdominal discomfort	55.87	32.93	4	13519	477324	90137600
Hypersensitivity	55.64	32.93	3	13520	454674	90160250
Pneumothorax	55.56	32.93	35	13488	19132	90595792
Breast cancer recurrent	54.49	32.93	23	13500	5480	90609444
Polyneuropathy	52.78	32.93	34	13489	19307	90595617
Folate deficiency	51.68	32.93	19	13504	3146	90611778
Lymphopenia	49.91	32.93	35	13488	22846	90592078
Drug hypersensitivity	48.66	32.93	6	13517	463603	90151321
Hepatic failure	48.18	32.93	43	13480	39685	90575239
Ascites	46.98	32.93	46	13477	47694	90567230
Tumour marker increased	46.83	32.93	21	13502	5786	90609138
Metastases to the mediastinum	45.79	32.93	12	13511	645	90614279
Platelet count decreased	45.69	32.93	77	13446	136892	90478032
Decreased appetite	45.19	32.93	141	13382	376399	90238525
Arthralgia	44.48	32.93	31	13492	778491	89836433
Odynophagia	43.59	32.93	23	13500	9020	90605904
Herpes simplex encephalitis	40.72	32.93	10	13513	413	90614511
Sepsis	39.97	32.93	85	13438	179729	90435195
Metastases to spinal cord	39.05	32.93	9	13514	282	90614642
Weight increased	38.04	32.93	8	13515	417919	90197005
Pruritus	37.45	32.93	17	13506	541508	90073416
Peripheral swelling	37.41	32.93	8	13515	413098	90201826
Pain	37.34	32.93	57	13466	996284	89618640
Metastases to bone marrow	36.94	32.93	10	13513	609	90614315
Metastases to pleura	36.09	32.93	13	13510	2031	90612893
Infusion related reaction	35.90	32.93	9	13514	416771	90198153
Protein total increased	35.86	32.93	15	13508	3494	90611430
Hyperglycaemia	35.72	32.93	41	13482	50929	90563995
Peripheral sensory neuropathy	34.86	32.93	20	13503	9230	90605694
Lymphangiosis carcinomatosa	34.73	32.93	12	13511	1660	90613264
Metastatic neoplasm	34.38	32.93	16	13507	4799	90610125
Swelling	34.30	32.93	10	13513	419048	90195876
Depression	33.80	32.93	3	13520	300598	90314326
Skin mass	33.29	32.93	18	13505	7412	90607512

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	99.53	41.39	48	510	185655	42435122
Neutropenia	93.28	41.39	47	511	199384	42421393
Myelosuppression	72.43	41.39	25	533	40436	42580341

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Myelosuppression	1757.09	30.19	570	11174	93770	110483785
Neutropenia	1165.16	30.19	630	11114	373990	110203565
Malignant neoplasm progression	919.23	30.19	421	11323	174146	110403409
Neutrophil count decreased	645.84	30.19	295	11449	120646	110456909
Febrile neutropenia	587.49	30.19	383	11361	316384	110261171
White blood cell count decreased	455.71	30.19	290	11454	229100	110348455
Neuropathy peripheral	324.45	30.19	214	11530	179063	110398492
Metastases to bone	282.00	30.19	111	11633	31261	110546294
Pseudocirrhosis	280.74	30.19	53	11691	870	110576685
Leukopenia	265.13	30.19	176	11568	148615	110428940
Interstitial lung disease	243.83	30.19	163	11581	139171	110438384
Metastases to liver	222.46	30.19	97	11647	35289	110542266
Disease progression	174.68	30.19	169	11575	243865	110333690
Metastases to lung	167.34	30.19	70	11674	22993	110554562
Breast cancer metastatic	142.06	30.19	51	11693	11130	110566425
Metastases to central nervous system	131.92	30.19	59	11685	22758	110554797
Osteonecrosis of jaw	108.26	30.19	66	11678	47951	110529604
Metastases to lymph nodes	103.60	30.19	44	11700	14988	110562567
Neoplasm progression	99.63	30.19	70	11674	64525	110513030
Pyrexia	87.29	30.19	250	11494	898015	109679540
Mucosal inflammation	86.96	30.19	76	11668	96065	110481490
Thrombocytopenia	84.96	30.19	141	11603	348744	110228811
Metastases to skin	81.81	30.19	23	11721	2276	110575279
Stomatitis	72.26	30.19	114	11630	270128	110307427
Palmar-plantar erythrodysaesthesia syndrome	64.50	30.19	45	11699	40980	110536575
Anaemia	62.69	30.19	162	11582	546924	110030631
Hepatic function abnormal	62.14	30.19	61	11683	89234	110488321
Pneumothorax	60.90	30.19	41	11703	35244	110542311
Hyperchlorhydria	60.70	30.19	18	11726	2151	110575404
Hormone receptor positive breast cancer	56.71	30.19	13	11731	564	110576991
Haematotoxicity	55.39	30.19	32	11712	21050	110556505
Breast cancer recurrent	54.38	30.19	19	11725	3827	110573728
Pneumonitis	49.04	30.19	50	11694	76481	110501074
Decreased appetite	48.50	30.19	135	11609	475711	110101844
Folate deficiency	48.05	30.19	18	11726	4420	110573135
Breast cancer	44.25	30.19	35	11709	38507	110539048
Pleural effusion	43.40	30.19	72	11672	177637	110399918
Metastases to the mediastinum	42.69	30.19	11	11733	782	110576773
Polyneuropathy	38.76	30.19	30	11714	31982	110545573
Herpes simplex encephalitis	37.23	30.19	10	11734	835	110576720
Platelet count decreased	37.01	30.19	78	11666	230365	110347190
Protein total increased	36.48	30.19	15	11729	4709	110572846
Odynophagia	35.97	30.19	21	11723	14080	110563475
Drug hypersensitivity	34.35	30.19	4	11740	454086	110123469
Hepatic failure	32.03	30.19	38	11706	68701	110508854
Hypersensitivity	31.99	30.19	3	11741	403995	110173560
Skin mass	31.51	30.19	17	11727	9799	110567756
Metastases to bone marrow	30.94	30.19	9	11735	1005	110576550
Recurrent cancer	30.33	30.19	12	11732	3411	110574144
Pruritus	30.21	30.19	12	11732	581548	109996007

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L01XX41	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS OTHER ANTINEOPLASTIC AGENTS Other antineoplastic agents
FDA PE	N0000175085	Microtubule Inhibition
FDA EPC	N0000175592	Microtubule Inhibitor
CHEBI has role	CHEBI:35610	antineoplastic agent
CHEBI has role	CHEBI:61951	microtubule-destabilising agent

Related Drugs by ATC class:

L01XX Other antineoplastic agents 33 drugs

adagrasibafliberceptaltretamineamsacrineanagrelidearsenic trioxideasparaginasebelzutifancalaspargase pegolcelecoxibdarinaparsindenileukin diftitox show all 33 →

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Liposarcoma	indication	254829001	DOID:3382
Metastatic Breast Carcinoma	indication
Constipation	contraindication	14760008	DOID:2089
Hypokalemia	contraindication	43339004
Chronic heart failure	contraindication	48447003
Bradycardia	contraindication	48867003
Prolonged QT interval	contraindication	111975006
Hypomagnesemia	contraindication	190855004
Pregnancy, function	contraindication	289908002
Thrombocytopenic disorder	contraindication	302215000	DOID:1588
Peripheral nerve disease	contraindication	302226006
Neutropenic disorder	contraindication	303011007	DOID:1227
Congenital long QT syndrome	contraindication	442917000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.2	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
1MG/2ML (0.5MG/ML)	HALAVEN	EISAI INC	N201532	Nov. 15, 2010	RX	SOLUTION	INTRAVENOUS	Sept. 13, 2025	REVISIONS TO THE PEDIATRIC USE SUBSECTION OF LABELING TO INCLUDE THE RESULTS FROM CLINICAL STUDIES E7389-G000-223 AND E7389-G000-213, CONDUCTED TO FULFILL A PEDIATRIC WRITTEN REQUEST
1MG/2ML (0.5MG/ML)	HALAVEN	EISAI INC	N201532	Nov. 15, 2010	RX	SOLUTION	INTRAVENOUS	March 13, 2026	PEDIATRIC EXCLUSIVITY

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Tubulin beta	Tumour-associated antigen	P07437 Q9H4B7 Q13885 Q9BVA1 Q13509 P04350 P68371 Q9BUF5 Q3ZCM7	TBB5_HUMAN TBB1_HUMAN TBB2A_HUMAN TBB2B_HUMAN TBB3_HUMAN TBB4A_HUMAN TBB4B_HUMAN TBB6_HUMAN TBB8_HUMAN	INHIBITOR	IC50	8.23		IUPHAR	SCIENTIFIC LITERATURE

External reference:

ID	Source
4030296	VUID
N0000182254	NUI
D08914	KEGG_DRUG
441045-17-6	SECONDARY_CAS_RN
4030296	VANDF
4030302	VANDF
C2350866	UMLSCUI
CHEMBL1683590	ChEMBL_ID
CHEMBL1683544	ChEMBL_ID
DB08871	DRUGBANK_ID
C490954	MESH_SUPPLEMENTAL_RECORD_UI
6813	IUPHAR_LIGAND_ID
8854	INN_ID
LR24G6354G	UNII
11354606	PUBCHEM_CID
1045452	RXNORM
178296	MMSL
27619	MMSL
385128	MMSL
d07716	MMSL
013558	NDDF
013559	NDDF
448800004	SNOMEDCT_US
708166000	SNOMEDCT_US
767582004	SNOMEDCT_US
CHEBI:70710	CHEBI
6K9	PDB_CHEM_ID
LR24G6354G	INXIGHT DRUGS

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
ERIBULIN MESYLATE	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9167	INJECTION	0.50 mg	INTRAVENOUS	ANDA	32 sections
Eribulin Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0781-3391	INJECTION	0.50 mg	INTRAVENOUS	ANDA	28 sections
Eribulin Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	10019-080	INJECTION	0.50 mg	INTRAVENOUS	ANDA	29 sections
Eribulin Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	10019-080	INJECTION	0.50 mg	INTRAVENOUS	ANDA	29 sections
ERIBULIN MESYLATE	HUMAN PRESCRIPTION DRUG LABEL	1	39822-2080	INJECTION	0.50 mg	INTRAVENOUS	ANDA	32 sections
ERIBULIN MESYLATE	HUMAN PRESCRIPTION DRUG LABEL	1	40033-364	INJECTION	0.50 mg	INTRAVENOUS	ANDA	33 sections
Eribulin Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	43598-125	INJECTION	0.50 mg	INTRAVENOUS	ANDA	27 sections
Halaven	HUMAN PRESCRIPTION DRUG LABEL	1	43624-002	INJECTION	1 mg	INTRAVENOUS	NDA	2 sections
eribulin mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	60505-6289	INJECTION	0.50 mg	INTRAVENOUS	ANDA	28 sections
eribulin mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	60505-6435	INJECTION	0.50 mg	INTRAVENOUS	ANDA	28 sections
Halaven	HUMAN PRESCRIPTION DRUG LABEL	1	62856-389	INJECTION	0.50 mg	INTRAVENOUS	NDA	33 sections
Halaven	HUMAN PRESCRIPTION DRUG LABEL	1	62856-389	INJECTION	0.50 mg	INTRAVENOUS	NDA	33 sections
Eribulin Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	68001-656	SOLUTION	0.50 mg	INTRAVENOUS	ANDA	30 sections
eribulin mesylate	Human Prescription Drug Label	1	68083-592	INJECTION	0.50 mg	INTRAVENOUS	ANDA	27 sections
ERIBULIN MESYLATE	HUMAN PRESCRIPTION DRUG LABEL	1	68462-770	INJECTION	0.50 mg	INTRAVENOUS	ANDA	33 sections
ERIBULIN MESYLATE	Human Prescription Drug Label	1	70095-080	INJECTION	0.50 mg	INTRAVENOUS	ANDA	28 sections
Eribulin Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	71731-4171	INJECTION	0.50 mg	INTRAVENOUS	ANDA	32 sections
Eribulin Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	72603-368	SOLUTION	0.50 mg	INTRAVENOUS	ANDA	32 sections
Eribulin Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	81298-3890	SOLUTION	0.50 mg	INTRAVENOUS	ANDA	30 sections